- Home
- OCUL vs MNKD Comparison
OCUL vs MNKD Comparison
Compare OCUL & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OCUL | MNKD |
|---|---|---|
| Founded | 2006 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.8B |
| IPO Year | 2014 | 2004 |
Fundamental Metrics
Financial Performance| Metric | OCUL | MNKD |
|---|---|---|
| Price | $9.11 | $5.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 6 |
| Target Price | ★ $22.56 | $10.08 |
| AVG Volume (30 Days) | ★ 6.1M | 4.0M |
| Earning Date | 02-05-2026 | 02-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 23.47 |
| EPS | N/A | ★ 0.10 |
| Revenue | $51,951,000.00 | ★ $313,787,000.00 |
| Revenue This Year | $20.43 | $21.29 |
| Revenue Next Year | $79.81 | $25.53 |
| P/E Ratio | ★ N/A | $59.56 |
| Revenue Growth | N/A | ★ 17.43 |
| 52 Week Low | $5.79 | $3.38 |
| 52 Week High | $16.44 | $6.51 |
Technical Indicators
Market Signals| Indicator | OCUL | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 36.76 | 49.35 |
| Support Level | $8.36 | $5.47 |
| Resistance Level | $9.69 | $6.05 |
| Average True Range (ATR) | 0.67 | 0.31 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 27.37 | 34.71 |
Price Performance
Historical ComparisonAbout OCUL Ocular Therapeutix Inc.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.